Ignite Creation Date:
2025-12-25 @ 2:45 AM
Ignite Modification Date:
2025-12-30 @ 2:51 PM
Study NCT ID:
NCT05903833
Status:
RECRUITING
Last Update Posted:
2025-09-09
First Post:
2023-05-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Sponsor:
AGO Research GmbH
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-06-24
Start Date Type:
ACTUAL
Primary Completion Date:
2027-10-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-10-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-11
First Submit QC Date:
None
Study First Post Date:
2023-06-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-08
Last Update Post Date:
2025-09-09
Last Update Post Date Type:
ESTIMATED